NOVA:FRA
Novo
35,66 €
arrow_downward
−0,39%(−0,14) 1D
19. nov., 15:50:02 GMT +1 · EUR
search
Vsi simboli
| Simbol | Cena | Sprememba | Odstotna sprememba |
|---|
insights_autoGeneriranje najpomembnejših vpogledov za NOVA …
Odpri
35,70 €
Visoka
36,28 €
Nizka
35,42 €
Tržna kapitalizacija
133,46 mrd.
Povprečni promet
650,00
Promet
1,53 tis.
52-tedenski najvišji tečaj
54,80 €
52-tedenski najnižji tečaj
30,45 €
Št. zaposlenih
67 tis.
Odpri
35,70 €
Visoka
36,28 €
Nizka
35,42 €
Tržna kapitalizacija
133,46 mrd.
Povprečni promet
650,00
Promet
1,53 tis.
52-tedenski najvišji tečaj
54,80 €
52-tedenski najnižji tečaj
30,45 €
Št. zaposlenih
67 tis.
Novice
Iz spletnih virov in novičarskih partnerjev
The Business Journals
·
pred 8 urami
Novo taps Cambridge AI biotech for obesity, diabetes collab
Traders Union
·
pred 10 urami
Will Novo Nordisk stock avoid deeper losses amid seller dominance?
TradingKey
·
pred 22 urami
Novo Nordisk A/S Stock (NVO) Moved Down by 3.12% on Nov 18: What Investors Need To Know
Yahoo Finance
·
pred 1 dnevom
Novo Nordisk (NVO) Stock May Be Undervalued On Raised 2026 Outlook
Profil
Novo Nordisk A/S, doing business as Novo, is a Danish multinational pharmaceutical company. Novo manufactures and markets pharmaceutical products and services, primarily obesity and diabetes medications and devices. The corporation was created in 1989, through a merger of two Danish pharmaceutical companies, which date back to the 1920s.
Novo employs approximately 69,500 people in 80 countries, and markets its products in approximately 170 countries. Novo is controlled by majority shareholder Novo Holdings which holds 28% of its shares and a majority of its voting shares.
Novo is a full member of the European Federation of Pharmaceutical Industries and Associations.
The company was ranked 25th among Fortune's 100 Best Companies to Work For in 2010, and subsequently ranked 72nd in 2014 and 73rd in 2017. In January 2012, Novo was named the most sustainable company in the world by the business magazine Corporate Knights. It is a leader in the FTSE4Good Index, and the only European company in the top ten.
Novo is the largest pharmaceutical company in Denmark. In 2023, Novo's market capitalization exceeded the GDP of Denmark, and it became the highest valued company in Europe. Wikipedia
Vizitka: Novo
Generalni direktorMike Doustdar
Št. zaposlenih66,7 tis.
Ustanovljeno1923
SedežBagsværd, Capital Region of Denmark, Danska
SektorHealth Care
Panoga-
Spletno mestonovonordisk.com